Related Experiment Video

Updated: May 1, 2026

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

2.1K

[Association between the single nucleotide polymorphisms of human CD36 gene and acute coronary syndrome]

Junyi Luo1, Yitong Ma1, Xiang Xie1

  • 1Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.

Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi
|April 18, 2014
PubMed

Insights

Genetic variations in the CD36 gene are associated with acute coronary syndrome (ACS) in Han and Uygur populations. These CD36 gene polymorphisms may serve as valuable genetic markers for ACS risk assessment.

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Acute coronary syndrome (ACS) is a major cause of mortality worldwide.
  • Genetic factors play a significant role in the development of ACS.
  • The CD36 gene is implicated in lipid metabolism and inflammatory processes relevant to atherosclerosis.

Purpose of the Study:

  • To investigate the association between CD36 gene single nucleotide polymorphisms (SNPs) and the risk of developing ACS.
  • To evaluate potential differences in these associations across ethnic groups.

Main Methods:

  • Genotyping of CD36 SNPs was performed using PCR-RFLP.
  • The study included 522 patients diagnosed with ACS and 1,215 healthy controls.
  • Logistic regression analysis was employed to assess the odds ratios and confidence intervals.

Main Results:

  • Significant differences in genotype and allele distributions for rs1722505 were observed between ACS patients and controls in both Han and Uygur populations (P < 0.05).
  • For the Han population, the A allele frequency of rs17154181 was lower in ACS patients (P = 0.034).
  • The AA+AG genotype of rs1722505 was significantly associated with increased ACS risk in both ethnic groups (ORs ranging from 1.436 to 1.589).
  • In Han individuals, the AA+AG genotype of rs17154181 was associated with a reduced risk of ACS (OR = 0.667).

Conclusions:

  • The findings suggest that specific CD36 gene polymorphisms are associated with ACS.
  • CD36 gene variants may function as genetic markers for ACS in Han and Uygur populations.
  • Further research is warranted to elucidate the precise mechanisms underlying these associations.
Abstract

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K
High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.4K

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
943
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.6K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.6K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121